BeiGene Co., Ltd. is a global biotechnology company. The company focuses on discovering, developing, manufacturing and commercializing drugs to improve treatment effectiveness and expand access to patients around the world. The company has discovered and developed three approved drugs, including BRUKINSA, a small molecule inhibitor of Bruton tyrosine kinase (BTK) for the treatment of various blood cancers, tislelizumab for anti-PD-1 antibody immunotherapy for a variety of solid tumors and blood cancers, and pamiparib, a selective small molecule inhibitor for poly ADP ribose polymerase 1 (PARP1) and PARP2. The company also has other clinical products, including BGB-283, BGB-3245, BGB-11417, BGB-A445, BGB-A425, BGB-15025, BGB-A333, BGB-A1217 and BGB-10188. The company has offices in about 30 countries on five continents, including the United States, China, Europe and Australia.